A ROP prediction AI
to save children from blindness.
Analyzing vital data with AI and support the healthy growth of prematured newborns.
Empowering Healthy Growth Through AI-Powered Medical Innovation
At NeoCure Inc., we leverage AI to analyze neonatal vital signs and detect disease risks early—supporting the healthy development of newborns. We are developing an advanced Software as a Medical Device (SaMD) that predicts Retinopathy of Prematurity (ROP) progression using non-invasive, routinely collected NICU data.
ROP is the leading cause of childhood blindness, affecting over 30,000 children globally and costing over USD 70 billion. Although treatments exist, they must be given within a few critical days. A global shortage of pediatric ophthalmologists makes timely diagnosis difficult. Our AI solution identifies high-risk infants early, enabling timely and targeted care. A prototype with 90% prediction accuracy has already been developed, and we are advancing toward clinical application. NeoCure Inc. is committed to ending childhood blindness from ROP through innovative, accessible technology.
NeoCure Inc. is committed to eliminating childhood blindness from ROP through innovative, accessible medical technology.
Vision & Project
NeoCure's Vision
Project Overview
Member and Company Introduction
Ryo Kawasaki
CSO
Professor, Graduate School of Medicine, Osaka University (Ph.D.).
A ophthalmologist leading medical strategy with broad healthcare expertise.
Yoko Fukushima
CEO
Specially Appointed Associate Professor, Osaka University School of Medicine (Ph.D.)
A neonatal ophthalmologist fully engaged in both clinical practice and research.
Responsible for technology development.
Motoshi Sobue
Representative Director
Project Professor at NAIST (Ph.D.).
A serial entrepreneur and experienced MNC executives.
Responsible for overall management.
NeoCure Inc.
Kotani BLDG 3F, 686-3 Ebisuno, Shimogyo-ku, Kyoto, Japan 600-8310
Representative Director Motoshi Sobue
info@neocure.jp
English 
Japanese